Flatiron Health Highlights 18 Accepted Studies Leveraging Real-World Data for Presentation at ISPOR 2026
Flatiron Health has announced a significant presence at the ISPOR Annual Meeting 2026, taking place from May 17 to May 20, 2026, in Philadelphia. The company’s participation underscores its growing influence in the fields of oncology real-world evidence (RWE), health economics, and outcomes research, particularly as artificial intelligence (AI) and large language models (LLMs) continue to reshape how clinical data is generated, validated, and applied in decision-making.
At this year’s meeting, Flatiron Health is contributing to more than 18 accepted research presentations, including seven posters authored by its own researchers. The breadth of these contributions reflects the company’s ongoing investment in high-quality real-world data (RWD) and its commitment to advancing methodologies that support regulatory, clinical, and payer decision-making. A central highlight of its presence is a featured panel session titled “Beyond Black Boxes: Transparent, Validated LLM Workflows for Accelerating Global HTA Submissions and Decisions,” which will explore how AI-driven workflows can be made more transparent, reliable, and fit for purpose in high-stakes healthcare environments.
Flatiron’s participation at ISPOR 2026 comes shortly after the publication of its VALID (Validation of Accuracy for LLM/ML-Extracted Information and Data) framework in the Journal of Clinical Oncology Clinical Cancer Informatics. This framework represents a major milestone in oncology research, offering what is described as the first comprehensive, peer-reviewed methodology for evaluating the quality and reliability of real-world data extracted using LLMs and machine learning tools. By establishing standardized approaches to validation, the framework aims to address growing concerns about data integrity and reproducibility in AI-enabled research.
Emily Castellanos, MD, MPH, Senior Medical Director and Head of Research Oncology at Flatiron Health, emphasized the importance of rigorous validation in the era of AI-driven research. She noted that rapid advancements in LLMs and related technologies have made it essential to adopt thoughtful and systematic approaches to data quality and methodology. According to Castellanos, Flatiron’s strong presence at ISPOR reflects its broader mission to deliver high-fidelity, decision-ready real-world evidence and to maintain its position as a trusted partner for clinical and research stakeholders making critical decisions.
Expanding the frontiers of real-world evidence in oncology
Among the key research highlights presented by Flatiron Health are several studies demonstrating innovative applications of AI and advanced analytics in oncology. One such study evaluates an LLM-based approach that integrates prostate-specific antigen (PSA) levels with imaging data to derive real-world progression events in prostate cancer. This approach aims to improve the accuracy and completeness of disease progression tracking, a critical factor in assessing treatment effectiveness outside of controlled clinical trials.
Another notable study focuses on the development and evaluation of digital twin models—computational representations of individual patients—that can be used to predict survival outcomes in advanced non-small cell lung cancer. By simulating patient trajectories, these models have the potential to support personalized treatment strategies and enhance clinical trial design.
Flatiron researchers are also presenting an application of the VALID framework to assess the quality of an LLM-derived prostate cancer dataset. This work demonstrates how standardized validation methods can be applied in practice, providing greater confidence in AI-generated datasets used for research and regulatory purposes.
In addition, Flatiron is involved in a collaborative pilot project led by Friends of Cancer Research, which examines the feasibility of using real-world data to support external control arms in oncology studies. The findings highlight that the success of such approaches depends heavily on data quality, methodological consistency, and careful study design—factors that are increasingly important as real-world evidence gains traction in regulatory decision-making.
Key speaking session on AI transparency and HTA
A major highlight of Flatiron’s engagement at ISPOR 2026 is its participation in the panel discussion on transparent and validated LLM workflows for global health technology assessment (HTA). Moderated by Beth Devine, the session will feature speakers Bill Malcolm, Tim Reason, and Lockwood Taylor, and is scheduled for Wednesday, May 20, from 10:00 to 11:00 AM ET.
This session is expected to address one of the most pressing challenges in healthcare analytics today: how to ensure that AI-driven tools are not only powerful but also interpretable, reproducible, and trustworthy. As HTA bodies around the world increasingly rely on real-world evidence to inform reimbursement and policy decisions, the need for transparent AI methodologies has become paramount.
Diverse portfolio of research presentations
Flatiron’s contributions to ISPOR 2026 span a wide range of topics, reflecting the diversity of its research portfolio. Poster presentations include studies on real-world treatment patterns and outcomes in endometrial cancer, analyses of telemedicine’s impact on survival outcomes using electronic health record (EHR)-derived data, and investigations into cross-country survival modeling.
Additional research explores the customization of LLM approaches to capture clinically meaningful endpoints, as well as the development of patient-level counterfactual models using real-world data. These studies collectively demonstrate how advanced analytics and AI can be leveraged to generate deeper insights into patient outcomes and treatment effectiveness.
The company is also contributing to research on external control arm feasibility, involving collaborations with multiple organizations including the Pancreatic Cancer Action Network, AbbVie, Amgen, Genentech, and the American Society of Clinical Oncology. This multi-stakeholder effort highlights the collaborative nature of advancing real-world evidence in oncology and the importance of aligning methodologies across the industry.
Strengthening engagement with the research community
Attendees at ISPOR 2026 will have the opportunity to engage directly with Flatiron Health at booth #316, where the company will showcase its latest innovations in real-world data and oncology research. The company is also encouraging participants to follow its updates on social media platforms, including X and LinkedIn, for real-time insights and highlights from the conference.
Driving the future of oncology intelligence
Flatiron Health’s robust presence at ISPOR 2026 reflects its leadership in the rapidly evolving landscape of real-world evidence and AI-driven research. By combining high-quality data with rigorous validation frameworks and innovative analytical approaches, the company is helping to set new standards for how oncology data is generated, interpreted, and applied.
As healthcare systems worldwide continue to seek more efficient and evidence-based ways to evaluate treatments and allocate resources, the role of real-world data and AI will only grow in importance. Through initiatives like the VALID framework and its extensive research contributions, Flatiron Health is positioning itself at the forefront of this transformation—bridging the gap between data and decision-making, and ultimately supporting better outcomes for patients with cancer.
About Flatiron
Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.
Source Link:https://www.businesswire.com/
